Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) that predominate in non-small cell lung cancer (NSCLC) tumours following treatment with first-line EGFR-TKIs². It exhibits a nine-fold greater affinity for select EGFR-sensitizing and T790M-resistance mutations than to wild-type EGFR¹.

(1) . https://bing.com/search?q=osimertinib+mechanism+of+action. (2) DRUG NAME: Osimertinib - BC Cancer. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Osimertinib_monograph.pdf. (3) Mechanism of Action – TAGRISSO® (osimertinib). https://www.tagrissohcp.com/moa.html. (4) Osimertinib: Uses, Interactions, Mechanism of Action | DrugBank Online. https://go.drugbank.com/drugs/DB09330. (5) Mechanisms of osimertinib resistance and emerging treatment ... - PubMed. https://pubmed.ncbi.nlm.nih.gov/32693293/.